共 807 条
[1]
Gold R(2005)The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study Eur J Neurol 12 649-656
[2]
Rieckmann P(2010)Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate Mult Scler 16 342-350
[3]
Chang P(2019)CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date Expert Opin Biol Ther 19 829-843
[4]
Abdalla J(2006)A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 899-910
[5]
Ford C(2015)Sphingosine 1-phosphate receptor modulators in multiple sclerosis CNS Drugs 29 565-575
[6]
Goodman AD(2019)Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis J Mol Med (Berl) 97 463-472
[7]
Johnson K(2015)Alemtuzumab in multiple sclerosis: mechanism of action and beyond Int J Mol Sci 16 16414-16439
[8]
Kachuck N(2014)Teriflunomide and its mechanism of action in multiple sclerosis Drugs. 74 659-674
[9]
Lindsey JW(2010)A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis N Engl J Med 362 416-426
[10]
Lisak R(2014)Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study J Clin Oncol 32 3736-3743